Last €3.22 EUR
Change Today +0.013 / 0.41%
Volume 1.0K
NZW1 On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 5:58 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

threshold pharmaceuticals (NZW1) Snapshot

Open
€3.22
Previous Close
€3.21
Day High
€3.22
Day Low
€3.16
52 Week High
09/9/14 - €4.33
52 Week Low
11/6/14 - €2.09
Market Cap
202.1M
Average Volume 10 Days
962.5
EPS TTM
--
Shares Outstanding
62.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THRESHOLD PHARMACEUTICALS (NZW1)

threshold pharmaceuticals (NZW1) Related Businessweek News

No Related Businessweek News Found

threshold pharmaceuticals (NZW1) Details

Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; and various earlier-stage clinical trials for therapeutic areas, including advanced leukemias, multiple myeloma, advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Threshold Pharmaceuticals, Inc. has a license and co-development agreement with Merck KGaA to co-develop and commercialize TH-302; and license agreement with Eleison Pharmaceuticals, Inc. for the development and commercialization of glufosfamide for the treatment of cancer in humans and animals. The company was founded in 2001 and is headquartered in South San Francisco, California.

61 Employees
Last Reported Date: 11/3/14
Founded in 2001

threshold pharmaceuticals (NZW1) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $575.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $263.0K
Chief Medical Officer
Total Annual Compensation: $361.0K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $301.7K
Vice President of Pharmaceutical Development ...
Total Annual Compensation: $274.0K
Compensation as of Fiscal Year 2013.

threshold pharmaceuticals (NZW1) Key Developments

Threshold Pharmaceuticals, Inc. Announces New Preliminary Data from the Phase 2 Component of an Ongoing Company-Sponsored Phase 1/2 Trial of Th-302

Threshold Pharmaceuticals Inc. announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade) and low-dose dexamethasone ("TBorD") for the treatment of patients with relapsed/refractory multiple myeloma (MM). The median number of prior therapies was 8 (range, 4-12). The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses (one very good partial response and one partial response) were observed in 2 of 7 (29%) evaluable patients overall and 2 of 4 (50%) evaluable patients at the recommended phase 2 dose of TH-302. The ongoing Phase 1/2 trial is investigating TH-302 and dexamethasone with or without bortezomib with respect to safety and tolerability, dose-limiting toxicities and the maximum-tolerated dose of TH-302, and preliminary efficacy in patients with relapsed/refractory MM. A total of 18 patients with relapsed/refractory MM have been enrolled in the Phase 2 TBorD component of the study as of November 17, 2014. Key data from TBorD dosing cohorts: boldPreliminary assessment of safety and tolerability No dose limiting toxicities were reported during Cycle 1 at TH-302 doses of 240 mg/m² or 340 mg/m². The maximum tolerated dose of TH-302 with dexamethasone had previously been established at 340 mg/m2, and dose escalation above that dose of TH-302 with dexamethasone plus bortezomib was not allowed.(1) Therefore, after 6 patients had been treated at 340 mg/m2 without a dose limiting toxicity, the recommended Phase 2 dose of TH-302 in TBorD was established at 340 mg/m2. Safety data were available for 8 of 9 patients. The most common Grade 3/4 hematological adverse events were thrombocytopenia (reported in 4 patients), anemia (reported in 2 patients), and lymphopenia (reported in 2 patients). Fatigue (reported in 5 patients; one Grade 3/4) and nausea (reported in 4 patients; one Grade 3/4) were the most common non-hematological adverse events. Five serious adverse events (SAEs) were reported in 4 patients. One SAE of thrombocytopenia was considered related to TH-302. Skin toxicity, an adverse event of interest with TH-302, was limited: a Grade 2 rash resulting in treatment delay was reported at the 240 mg/m2 dose of TH-302, and one Grade 2 skin lesion with no impact on treatment was reported at the 340 mg/m2 dose of TH-302. There were no deaths related to the study drug.

Threshold Pharmaceuticals Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 11:30 AM

Threshold Pharmaceuticals Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 11:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Harold E. Selick, Executive Chairman and Chief Executive Officer.

Threshold Pharmaceuticals Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 11:30 AM

Threshold Pharmaceuticals Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 11:30 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Harold E. Selick, Executive Chairman and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NZW1:GR €3.22 EUR +0.013

NZW1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NZW1.
View Industry Companies
 

Industry Analysis

NZW1

Industry Average

Valuation NZW1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THRESHOLD PHARMACEUTICALS, please visit www.thresholdpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.